UK markets closed

ImmunoGen, Inc. (IMGN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
5.69+0.17 (+3.08%)
At close: 4:00PM EDT
5.65 -0.04 (-0.70%)
After hours: 05:36PM EDT
Currency in USD

Valuation measures

Market cap (intra-day) 51.15B
Enterprise value 3894.7M
Trailing P/E N/A
Forward P/E 1-7.02
PEG ratio (5-yr expected) 1N/A
Price/sales (ttm)8.40
Price/book (mrq)16.64
Enterprise value/revenue 36.55
Enterprise value/EBITDA 7-26.02

Trading information

Stock price history

Beta (5Y monthly) 1.32
52-week change 340.10%
S&P500 52-week change 331.46%
52-week high 310.88
52-week low 33.38
50-day moving average 36.12
200-day moving average 37.31

Share statistics

Avg vol (3-month) 31.86M
Avg vol (10-day) 31.36M
Shares outstanding 5201.62M
Implied shares outstanding 6N/A
Float 182.24M
% held by insiders 10.50%
% held by institutions 192.34%
Shares short (14 Jul 2021) 420.27M
Short ratio (14 Jul 2021) 412.65
Short % of float (14 Jul 2021) 411.43%
Short % of shares outstanding (14 Jul 2021) 410.12%
Shares short (prior month 14 Jun 2021) 423.07M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Jun 2021


Profit margin -40.82%
Operating margin (ttm)-26.73%

Management effectiveness

Return on assets (ttm)-7.99%
Return on equity (ttm)-253.87%

Income statement

Revenue (ttm)136.64M
Revenue per share (ttm)0.72
Quarterly revenue growth (yoy)12.80%
Gross profit (ttm)17.71M
EBITDA -34.38M
Net income avi to common (ttm)-55.78M
Diluted EPS (ttm)-0.29
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)239.54M
Total cash per share (mrq)1.19
Total debt (mrq)21.27M
Total debt/equity (mrq)31.07
Current ratio (mrq)2.28
Book value per share (mrq)0.34

Cash flow statement

Operating cash flow (ttm)-110.61M
Levered free cash flow (ttm)-4.13M